Foghorn Therapeutics Inc.
FHTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Foghorn Therapeutics Inc. focuses on Biotechnology services and products. Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin. The company carries a $247.8M market cap, placing it firmly in the micro-cap category. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Market Cap
$247.8M
Beta
2.89
P/E (TTM)
—
P/E (Fwd)
-4.54
EPS (TTM)
$-1.17
EPS (Fwd)
$-0.93
ROE
—
ROA
-21.0%
Cash
$183.6M
Total Debt
$42.0M
Free CF
-$36.9M
52W Change
-12.8%
Annual Financials
Cash vs Debt
With $183.6M in cash and $42.0M in debt, FHTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$36.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $19.2M (2022) to $30.9M (2025), reflecting a 61% increase over the period.
A beta of 2.89 means FHTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, FHTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Foghorn Therapeutics Inc. and its sector.